Value of Screening MRI Brain in Stage IV Non-small Cell Lung Cancer (VULCAN)

University Medical Center Groningen (UMCG)

Status: Enrolling

Conditions: Non Small Cell Lung Cancer Metastatic

Treatments: Diagnostic Test: MRI

Study type: Interventional

Funder types: Other

Identifiers

NCT05864794

NL16776

Details and patient eligibility

About

Patients with newly diagnosed stage IV non-oncogene addicted NSCLC, who are fit for systemic treatment and don't have any symptoms of brain disease will undergo an MRI of the brain to screen for brain disease.

Enrollment: 100 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Histologically or cytologically confirmed stage IV metastatic NSCLC, not amenable to curative treatment.
• Fit for systemic treatment (PS 0-2) according to standard of care.
• No symptoms of brain disease disease assessed according to standard clinical care by the thoracic oncologist.

Exclusion criteria

• Prior/concomitant therapy for stage IV disease.
• Oncogenic diver mutation (e.g. EGFR, ALK, ROS1, RET, MET, and BRAF) with approved targeted treatment.
• Contraindications for MRI scan with contrast as per standard of care protocol of the institution.

Trial design

Primary purpose: Screening

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

100 participants in 1 patient group

Screening population

Experimental group

Description:

Patients with newly diagnosed stage IV non-oncogene addicted NSCLC, who are fit for systemic treatment and don't have any symptoms of brain disease.

Treatment:

Diagnostic Test: MRI